3,141 results match your criteria Journal of Drugs in Dermatology[Journal]


Principles of Moisturizer Product Design

J Drugs Dermatol 2019 Jan;18(1s):s89-95

Moisturizers provide significant benefit in dermatology – as adjuvant therapy for many clinical conditions, as a key player in anti-aging regimens, and as a core component in maintaining healthy skin barrier function. Although they have been a mainstay for decades, lotions and creams are no longer formulated with a one-size-fits-all approach, where thickness was the primary cue for efficacy. In fact, moisturizer design today has become an art as well as a science. Read More

View Article

Download full-text PDF

Source
January 2019
10 Reads

Recent Advances in Mild and Moisturizing Cleansers

J Drugs Dermatol 2019 Jan;18(1s):s80-88

Mild and moisturizing cleanser technologies, and the science underpinning them, have progressed significantly over the past decade. This includes introduction of amino-acid based milder surfactants into the cleansing arena, a deeper understanding of the roles of stratum corneum lipids and proteins in their interaction with cleanser surfactants, the role of pH in skin cleansing, and the development of improved methodologies for predicting skin irritation and drying potential of cleansers. In this paper, the recent advances in these areas as well as newer technologies are reviewed, and the future directions are outlined. Read More

View Article

Download full-text PDF

Source
January 2019

The Importance of Understanding Consumer Preferences for Dermatologist Recommended Skin Cleansing and Care Products

J Drugs Dermatol 2019 Jan;18(1s):s75-79

Dermatologist recommendations of skin care products are critical to the management of compromised and healthy skin and appreciated by patients. Professionals must carefully weigh not only the safety and efficacy but also the aesthetics of products if they are to achieve the desired outcome of satisfied patients. This article elucidates the relevance of product sensory characteristics and consumer preferences, with specific focus on what appeals to men vs. Read More

View Article

Download full-text PDF

Source
January 2019

The Spectrum of Sensitive Skin: Considerations for Skin Care in Vulnerable Populations

J Drugs Dermatol 2019 Jan;18(1s):s68-74

Sensitive skin is a multifactorial condition, where the underlying pathology is not fully understood, and the clinical signs may not always be present or obvious. Despite this challenge, there has been recent progress to understand the different subtypes of sensitive skin, as well as new methods to measure the sensorial response that may not be obvious from visual examination. Similarly, there has been progress in understanding in the management of symptoms through skin care regimens designed for sensitive skin. Read More

View Article

Download full-text PDF

Source
January 2019

Skin Barrier Insights: From Bricks and Mortar to Molecules and Microbes

Authors:
Carol A. Bosko

J Drugs Dermatol 2019 Jan;18(1s):s63-67

Recent advances in genomics, spectroscopy, and immunology have increased our understanding of the skin barrier. A new model of barrier lipid organization has emerged owing to the application of advanced modeling and microscopy techniques. The contribution of filaggrin gene mutations to atopic dermatitis has increased our appreciation of the role barrier perturbations play in inflammatory dermatoses. Read More

View Article

Download full-text PDF

Source
January 2019
2 Reads

Concurrent Scabies Incognito and Crusted Scabies With Scalp Lesions Masquerading as Erythrodermic Dermatitis: Scabies Surrepticius in an Immunosuppressed Nonagenarian With Hyperkeratotic Plaques on her Head

Authors:
Philip R. Cohen

J Drugs Dermatol 2019 01;18(1):105

I read with interest the excellent report by Tolkachjhov et al1 that describes the delay in diagnosis of a scabies infestation in a 90-year-old woman. Her condition mimicked dermatitis not only on clinical presentation but also on evaluation of skin biopsies. Read More

View Article

Download full-text PDF

Source
January 2019
2 Reads

Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy

J Drugs Dermatol 2019 Jan;18(1):103-104

Novel immunotherapies including antibodies to programmed death ligand 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have become common therapies for neoplasms including metastatic melanoma and non-small cell lung cancer (NSCLC). Dermatologic toxicity is the most common adverse event associated with these immunotherapies. We report a case of bullous pemphogoid (BP) in a patient receiving combination durvalumab and tremelimumab, two newer immunotherapy checkpoint inhibitors under investigation in phase III trials. Read More

View Article

Download full-text PDF

Source
January 2019
3 Reads

Managing the Aesthetic Patient

J Drugs Dermatol 2019 Jan;18(1):92-102

wide variety of therapeutic options, some challenges have arisen: designing an adequate treatment plan, electing the most suitable procedures for the patient, taking into consideration the rheological characteristics of the products, considering the amount needed to achieve a natural look, but also defining the safest way to deliver the treatment. Aging of the facial structural tissue layers occurs at a different pace and the requirements for the aesthetic approach of a 30-year-old patient are different from a 60-year-old patient. A group of twelve experts in minimally invasive injectable procedures sought to identify common changes observed in different age groups in order to help in establishing a plan of treatment for patients of different ages. Read More

View Article

Download full-text PDF

Source
January 2019
1 Read

Open-Label, Post-Marketing Study to Evaluate the Performance and Safety of Calcium Hydroxylapatite With Integral Lidocaine to Correct Facial Volume Loss

Authors:
Gabriele F. Muti

J Drugs Dermatol 2019 Jan;18(1):86-91

Background: Calcium hydroxylapatite (CaHA, Radiesse®) with integral 0.3% lidocaine (CaHA(+)) has recently been approved for use in aesthetic medicine. This study assessed the performance of CaHA(+) in subjects undergoing treatment for facial volume loss and evaluated subject and physician satisfaction. Read More

View Article

Download full-text PDF

Source
January 2019
4 Reads

Cohort Using a Ceramides Containing Cleanser and Cream With Salicylic Acid for Dry, Flaking, and Scaling Skin Conditions

J Drugs Dermatol 2019 Jan;18(1):80-85

Introduction: The skin of subjects with dry, flaking, and/or scaling conditions is characterized by decreased water and skin lipids content among other findings. It is well understood that daily use of gentle cleansers and moisturizers may help to restore and maintain an optimal skin barrier function. A cohort study of patients with dry skin was developed to evaluate efficacy of daily use of a ceramide containing cleanser and cream that also has salicylic acid. Read More

View Article

Download full-text PDF

Source
January 2019
8 Reads

Patient Satisfaction Following Treatment With Microfocused Ultrasound With Visualization: Results of a Retrospective Cross-Sectional Survey

J Drugs Dermatol 2019 Jan;18(1):75-79

Background: A device that uses microfocused ultrasound with visualization (MFU-V) is cleared in the United States and European Union as a noninvasive procedure that lifts and tightens the skin (Ultherapy® System; Merz North America, Raleigh, NC, USA). The objective of this patient survey was to obtain more in-depth information on patient satisfaction during the MFU-V treatment procedure and satisfaction with their aesthetic results. Methods: Survey participants had received MFU-V treatment and completed at least 6 months of follow-up. Read More

View Article

Download full-text PDF

Source
January 2019

Open Label Study Evaluating Efficacy, Safety, and Effects on Perception of Age After Injectable 20 mg/mL Hyaluronic Acid Gel for Volumization of Facial Temples

J Drugs Dermatol 2019 Jan;18(1):67-74

Objective: To study the safety, efficacy, optimal volume, and longevity of an injectable hyaluronic acid (HA) gel dermal filler to treat facial temporal fossa fat loss. Methods and materials: This open-label, single-site, 12-month study used 20 mg/mL HA gel to correct volume loss in both temples in 30 subjects. Touch-ups were allowed at week 2. Read More

View Article

Download full-text PDF

Source
January 2019
5 Reads

Effectiveness of Combining High-Intensity Focused Radiofrequency and Non-Ablative Fractional Laser for Improving the Appearance of the Aging Face and Neck

J Drugs Dermatol 2019 Jan;18(1):59-64

Background: The safety and effectiveness of high-intensity precision radiofrequency (RF) for rejuvenating the aging neck and face, and of fractional laser therapy for treating photodamaged skin have each been previously demonstrated. Objective: To assess the effects of combining high-intensity precision RF and fractional laser therapy for treating the aging face and neck. Methods and Materials: Subjects (N=19) with Fitzpatrick skin types I to VI and mild-to-moderate solar elastosis and sun or age-related pigmentation on the face and/or neck were sequentially treated with high-intensity precision RF and fractionated laser devices during the same session. Read More

View Article

Download full-text PDF

Source
January 2019
1 Read

IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A

J Drugs Dermatol 2019 Jan;18(1):52-57

Aesthetic dermatologic applications of botulinum neurotoxin (BoNT), including treatment of glabellar lines, horizontal forehead lines, and crow’s feet, were the most common non-surgical cosmetic procedures in the US in 2017, with high levels of subject satisfaction. Since the first BoNT type A (BoNT-A) formulation was approved in 1989, the number of formulations available on the world’s commercial markets has increased and new approvals are expected. BoNT is produced by Clostridium botulinum in nature as part of a large protein complex. Read More

View Article

Download full-text PDF

Source
January 2019

Final Data from the Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR)

J Drugs Dermatol 2019 Jan;18(1):40-48

Perceptions of attractiveness can be negatively affected by submental fullness. Patients seeking to improve their submental contour have a variety of treatment options including surgical procedures, energy-based devices, and injectable treatment. The Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR) was designed to provide insights into the treatment of submental fat (SMF) in clinical practice. Read More

View Article

Download full-text PDF

Source
January 2019
4 Reads

Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population

J Drugs Dermatol 2019 Jan;18(1):32-38

Background: Acne vulgaris (acne) is the most common dermatologic disease seen in a racially, geographically, politically, culturally, and socioeconomically diverse Hispanic population. Despite their growing demographics in the US, there are few studies evaluating acne treatment in this population. Potential for skin irritation and dryness, as well as pigmentary changes are key concerns. Read More

View Article

Download full-text PDF

Source
January 2019

A Novel Approach to Enhancing the Quality and Appearance of Photoaged Skin

J Drugs Dermatol 2019 Jan;18(1):28-31

Background: Moisturizers create the illusion of smooth, soft skin by placing a temporary film over the skin surface or by imparting a transient hydration benefit that does not clinically improve the quality or appearance of skin. Objective: The objective of this 8-week study was to assess the clinically relevant effects of a 3-step facial treatment program to improve the multiple qualities of photoaged skin. Methods: Thirty-five female subjects were evaluated at baseline and after 2, 4, and 8 weeks. Read More

View Article

Download full-text PDF

Source
January 2019
2 Reads

Seborrheic Dermatitis in Skin of Color: Clinical Considerations

J Drugs Dermatol 2019 Jan;18(1):24-27

Seborrheic dermatitis is a common, relapsing, inflammatory skin condition of unclear etiology. The Malassezia yeast genus are believed to play a role. Seborrheic dermatitis commonly affects areas of the skin with high sebum production, including the scalp, nasolabial folds, glabella, eyebrows, beard, ears, retroauricular skin, sternum, and other skin folds. Read More

View Article

Download full-text PDF

Source
January 2019

Update in Herpes Zoster Prevention and the Role of Dermatologists

J Drugs Dermatol 2019 Jan;18(1):18-22

A recombinant vaccine (HZ/su) was approved in 2017 to prevent herpes zoster (HZ) infection and associated sequelae with greater efficacy and safety than its live precursor. Though dermatologists regularly encounter patients with HZ infection, recommendation of vaccination by dermatologists and other physicians has been minimal in past years. Overall patient awareness and utilization of the HZ vaccines has subsequently been low. Read More

View Article

Download full-text PDF

Source
January 2019
5 Reads

Oral Collagen Supplementation: A Systematic Review of Dermatological Applications

J Drugs Dermatol 2019 Jan;18(1):9-16

Importance: The use of nutraceuticals such as collagen for skincare has been rising, but regulations are lacking on quality, absorption, and efficacy. To address this knowledge gap, clinical studies regarding the potential effects of collagen-based dietary supplements on skin are being completed. Objective: To review the literature and assess available randomized-controlled trials using collagen supplementation for treatment efficacy regarding skin quality, anti-aging benefits, and potential application in medical dermatology. Read More

View Article

Download full-text PDF

Source
January 2019
11 Reads

Retinoids in Acne Management: Review of Current Understanding, Future Considerations, and Focus on Topical Treatments

Authors:
Anna Chien

J Drugs Dermatol 2018 Dec;17(12):s51-55

Acne vulgaris is the most common skin condition affecting adolescents and young adults with a tremendous psychosocial impact. Its pathogenic hallmarks include follicular dyskeratosis, increased sebum production, and inflammation induced by Cutibacterium (formerly Propionibacterium) acnes within the follicle. Retinoids, derived from vitamin A, are the mainstays of acne treatment given they address the key pathogenic pathways of acne. Read More

View Article

Download full-text PDF

Source
December 2018
12 Reads

Retinoids in Acne Management: Review of Current Understanding, Future Considerations, and Focus on Topical Treatments

Authors:
Anna Chien

J Drugs Dermatol 2018 Dec;17(12):s51-55

Acne vulgaris is the most common skin condition affecting adolescents and young adults with a tremendous psychosocial impact. Its pathogenic hallmarks include follicular dyskeratosis, increased sebum production, and inflammation induced by Cutibacterium (formerly Propionibacterium) acnes within the follicle. Retinoids, derived from vitamin A, are the mainstays of acne treatment given they address the key pathogenic pathways of acne. Read More

View Article

Download full-text PDF

Source
December 2018
3 Reads

Evaluation, Prevention, and Management of Acne Scars: Issues, Strategies, and Enhanced Outcomes

J Drugs Dermatol 2018 Dec;17(12):s44-48

Acne is a common disease affecting a high percentage of the younger population. Without appropriate and effective primary prevention of scarring, post-acne scars occur in about 80-95% of all patients. Acne scarring is the result of an alteration of the healing process and it can have deep psychosocial implications for patients. Read More

View Article

Download full-text PDF

Source
December 2018
5 Reads

Acne and Scarring: Facing the Issue to Optimize Outcomes

Authors:
Jerry Tan

J Drugs Dermatol 2018 Dec;17(12):s43

This supplement summarize recent advances in the scientific understanding of acne pathogenesis as it relates to effective treatment acne in patients of all skin types and describes the role of retinoids in the management of acne and effective treatment and prevention strategies for hypertrophic and atrophic acne scarring in all skin types. Read More

View Article

Download full-text PDF

Source
December 2018
4 Reads

The Millennial Mindset

Authors:
Noëlle Sherber

J Drugs Dermatol 2018 Dec;17(12):1340-1342

The U.S. Census Bureau defines the Millennial generation as those born between 1982 and 2000, placing the upper age range at 36 years old. Read More

View Article

Download full-text PDF

Source
December 2018
3 Reads

Successful Treatment of Pemphigus Vulgaris With Ofatumumab

J Drugs Dermatol 2018 Dec;17(12):1338-1339

Rituximab is a chimeric anti-CD20 monoclonal antibody that is very effective in treating patients with pemphigus vulgaris. Though infrequent, the development of human anti-chimeric antibodies in patients receiving rituximab results in loss of efficacy. Ofatumumab is a second-generation fully-human anti-CD20 monoclonal antibody currently used to treat chronic lymphocytic leukemia. Read More

View Article

Download full-text PDF

Source
December 2018
4 Reads

Low-Grade Cutaneous B-cell Lymphoma in African American Patients

J Drugs Dermatol 2018 Dec;17(12):1334 - 1337

Introduction: Cutaneous marginal zone lymphoma (CMZL) and cutaneous follicle center lymphoma (CFCL) are rare indolent cutaneous B-cell lymphomas (CBCL). Their incidence in African American (AA) patients is extremely low. While cutaneous T-cell lymphomas appear to be more aggressive in AA individuals, there is no data on the presentation and course of disease of CBCL in this group. Read More

View Article

Download full-text PDF

Source
December 2018
4 Reads

Navigating Targeted Therapeutics in Dermatology: Biologics and Small Molecules

J Drugs Dermatol 2018 Dec;17(12):1330-1332

Dermatology is entering an exciting era with new, targeted immune-modulating medications for treating a variety of dermatologic conditions including psoriasis, atopic dermatitis (AD), and hidradenitis suppurativa. Previously, mainstay treatments consisted of topical corticosteroids or broad systemic immunosuppressants. Recently, our understanding of cytokine signaling cascades has grown, presenting new opportunities to target skewed immune responses. Read More

View Article

Download full-text PDF

Source
December 2018
5 Reads

Use of Apremilast for Aphthous Ulcers in a Patient With Behçet’s Syndrome

J Drugs Dermatol 2018 Dec;17(12):1328-1329

Behçet’s syndrome is an inflammatory disease characterized by aphthous oral ulcers and several systemic manifestations, which include genital ulcers, ocular disease, skin lesions, arthritis, and vascular disease Read More

View Article

Download full-text PDF

Source
December 2018
5 Reads

Rapidly Enlarging Malignant Proliferating Trichilemmal Tumor in a Young Female

J Drugs Dermatol 2018 Dec;17(12):1325-1327

Malignant proliferating trichilemmal tumors are rare adnexal neoplasms that most commonly occur on the scalp in elderly women. These tumors are associated with recurrence and even nodal or distant metastatic spread. Here we describe a 38-year-old patient who presented with a scalp nodule that was diagnosed as a high-grade malignant proliferating trichilemmal tumor. Read More

View Article

Download full-text PDF

Source
December 2018
4 Reads

Over-the-Counter Hair Loss Treatments: Help or Hype?

J Drugs Dermatol 2018 Dec;17(12):1317-1321

Introduction: A limited number of treatments have been approved for androgenetic alopecia, however, myriad over-the-counter products for hair loss are available and readily purchased by consumers. This study aims to provide an overview of popular over-the-counter hair loss products and to review the available evidence regarding their use. Methods: Top-selling hair loss products were identified using sales data from the online retailer Amazon. Read More

View Article

Download full-text PDF

Source
December 2018
3 Reads

Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging

J Drugs Dermatol 2018 Dec;17(12):1310-1315

Objective: To evaluate the safety and efficacy of ISDINCEUTICS Melaclear® serum (Barcelona, Spain) on skin brightness, skin quality, and signs of facial aging. Design: This was a single-center, observational, open label, prospective clinical study. Ten healthy females (ages 30-70) with moderate signs of facial aging and moderate photodamage (hyperpigmentation and/or sun spots) were enrolled. Read More

View Article

Download full-text PDF

Source
December 2018
13 Reads

Gastrointestinal Signs and Symptoms Related to Inflammatory Bowel Disease in Patients With Moderate-to-Severe Psoriasis

J Drugs Dermatol 2018 Dec;17(12):1298-1308

Background: Psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with comorbidities, including inflammatory bowel disease (IBD), given common immunopathogenic mechanisms. Whether PsO patients are more likely to suffer from gastrointestinal (GI) signs and symptoms has not been well-characterized. Understanding their prevalence in PsO patients may inform strategies to evaluate for GI signs and symptoms, screen for those at risk for IBD, and guide choice of therapy. Read More

View Article

Download full-text PDF

Source
December 2018
4 Reads

Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis

J Drugs Dermatol 2018 Dec;17(12):1290-1296

Background: A unique fixed combination halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) lotion has been shown to be effective in psoriasis using Investigator Global Assessment (IGA) tools to assess erythema, plaque elevation, and scaling. Read More

View Article

Download full-text PDF

Source
December 2018
2 Reads

Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy

J Drugs Dermatol 2018 Dec;17(12):1280-1287

Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Treatment options focus on relieving symptoms, reducing inflammation, induration, and scaling, and controlling the extent of the disease. While significant data on tazarotene in psoriasis has been available for over 20 years, its main utility is in acne. Read More

View Article

Download full-text PDF

Source
December 2018
3 Reads

Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy

J Drugs Dermatol 2018 Dec;17(12):1280-1287

Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Treatment options focus on relieving symptoms, reducing inflammation, induration, and scaling, and controlling the extent of the disease. While significant data on tazarotene in psoriasis has been available for over 20 years, its main utility is in acne. Read More

View Article

Download full-text PDF

Source
December 2018
2 Reads

Knowledge, Attitudes, and Perceptions of Cannabinoids in the Dermatology Community

J Drugs Dermatol 2018 Dec;17(12):1273-1278

Background: Recent research has identified potential uses of cannabinoids in dermatology, including psoriasis, atopic dermatitis, and wound healing. Objective: The extent of dermatologists’ familiarity with and interest in cannabinoids as therapeutics is unknown. Methods: This study examined dermatology providers’ knowledge, attitudes, and perceptions on therapeutic cannabinoids using a 20-question online survey. Read More

View Article

Download full-text PDF

Source
December 2018
7 Reads

Skin Cancer Prevention: A Review of Current Oral Options Complementary to Sunscreens

J Drugs Dermatol 2018 Dec;17(12):1266-1271

The incidence of non-melanoma skin cancer (NMSC) is dramatically increasing worldwide, despite the increased use of improved sunscreens. In 2014, the Surgeon General estimated that 2.2 to 5. Read More

View Article

Download full-text PDF

Source
December 2018
3 Reads

Using Google to Trend Patient Interest in Botulinum Toxin and Hyaluronic Acid Fillers

J Drugs Dermatol 2018 Nov;17(11):1245-1246

Introduction: Google Search is an important tool for patients researching skin care treatments and finding dermatologists. Data from individual patient’s searches are aggregated by Google and yield powerful data sets that can be used to trend population behaviors. This study investigates the correlations between the volume of Google searches and the number of procedures performed annually for both botulinum toxin type A and hyaluronic acid tissue fillers. Read More

View Article

Download full-text PDF

Source
November 2018
10 Reads
1.320 Impact Factor

Intralesional 5-Fluorouracil in the Treatment of Lower Leg Squamous Cell Carcinoma

J Drugs Dermatol 2018 Nov;17(11):1241-1243

Non-melanoma skin cancer (NMSC) is the most commonly diagnosed cancer in the United States.1,2 There are different treatment modalities for non-melanoma skin cancer, that include surgical excision, radiation therapy, cryotherapy, electrodessication and curettage, photodynamic therapy, and topical chemotherapy. Intralesional injection with 5-fluorouracil is a treatment modality that is not used often, perhaps due to not much research available to its effectiveness or established treatment recommendations. Read More

View Article

Download full-text PDF

Source
November 2018
9 Reads

Telogen Effluvium With Dysesthesia (TED) Has Lower B12 Levels and May Respond to B12 Supplementation

J Drugs Dermatol 2018 Nov;17(11):1236-1240

We investigated a subtype of Telogen Effluvium associated with Dysesthesia, (TED) which was defined as the presence of Telogen Effluvium with severe itch, pain, soreness, burning, or formication in the absence of any inflammatory scalp disorder or medication associated with Telogen Effluvium or Dysesthesia. These are patients who present with a “burning” scalp or other dysesthesia associated with increased telogen hair shedding. Telogen Effluvium is not typically associated with any scalp symptoms. Read More

View Article

Download full-text PDF

Source
November 2018
12 Reads

Nodules on the Nasal Tip: Think Before You Laser

J Drugs Dermatol 2018 Nov;17(11):1234-1235

View Article

Download full-text PDF

Source
November 2018
2 Reads

High Intensity Focused Electro-Magnetic Technology (HIFEM) for Non-Invasive Buttock Lifting and Toning of Gluteal Muscles: A Multi-Center Efficacy and Safety Study

J Drugs Dermatol 2018 Nov;17(11):1229-1232

Objective: Surgical intervention has been the only method to improve the aesthetic appearance of buttocks apart from physical exercising. This study evaluates the efficacy of high intensity focused electro-magnetic (HIFEM) treatments as a non-invasive solution for improvement of buttocks through toning and lifting of gluteal muscles. Materials and Methods: A total of 75 patients (aged 22-59) were treated using a device with HIFEM technology which stimulates gluteal muscles (EMSCULPT, BTL Industries, Boston, MA). Read More

View Article

Download full-text PDF

Source
November 2018
22 Reads

The Happy Face Treatment: An Anatomical-Based Technique for the Correction of Marionette Lines and the Oral Commissures

J Drugs Dermatol 2018 Nov;17(11):1226-1228

When viewing the most famous smiles in history (Figure 1), two constants become apparent: a smooth perioral surface and oral commissures that are turned upward (or horizontal as a minimum). Patients are often fixated on improving both the marionette lines and the downward oral commissures as these distractions are one of the most noticeable areas in the aging face to the average person. In addition, the downward turn of the oral commissures gives an impression of sadness. Read More

View Article

Download full-text PDF

Source
November 2018
3 Reads

Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test

J Drugs Dermatol 2018 Nov;17(11):1220-1223

Importance: The 31 gene-expression profiling test (31-GEP) has been shown to provide useful prognostic information in patients with cutaneous melanoma. The test dichotomizes patients into lower risk (Class 1) or higher risk (Class 2) for melanoma metastasis. Previous studies have demonstrated the clinical utility of the test in impacting dermatologists’ management decisions. Read More

View Article

Download full-text PDF

Source
November 2018
10 Reads

Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis

J Drugs Dermatol 2018 11;17(11):1211-1218

Objective: To assess the real-world risk of developing adverse medical conditions (AMCs) among patients with psoriasis treated with biologic therapies or conventional systemic/topical therapies (CST/topical). Methods: Adult patients with psoriasis were identified from the Truven MarketScan US claims database (2008 Q3–2015 Q3) and classified into cohorts based on treatment initiated on the index date (adalimumab [ADA], etanercept [ETN], ustekinumab [UST], infliximab [IFX], or CST/topical). Incident AMCs were identified while on treatment from diagnoses recorded in medical claims and included abnormal test results, infections, mental disorders, cardiovascular disease, malignancies (skin and non-skin), and respiratory disease. Read More

View Article

Download full-text PDF

Source
November 2018
2 Reads
1.320 Impact Factor

Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials

J Drugs Dermatol 2018 Nov;17(11):1201-1208

Background: Rosacea is a chronic dermatologic condition with limited treatment options. Methods: Data were pooled from two identically designed phase 3 trials. Patients with moderate to severe persistent erythema of rosacea were randomized to receive oxymetazoline cream 1. Read More

View Article

Download full-text PDF

Source
November 2018
15 Reads

Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females

J Drugs Dermatol 2018 Nov;17(11):1192-1198

Introduction: Acne vulgaris is more common in females than males and is challenging to treat. A post hoc analysis of 2 clinical trials evaluated the effect of dapsone gel, 7.5% based on sex and baseline acne lesion count. Read More

View Article

Download full-text PDF

Source
November 2018
10 Reads

Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females

J Drugs Dermatol 2018 Nov;17(11):1192-1198

Introduction: Acne vulgaris is more common in females than males and is challenging to treat. A post hoc analysis of 2 clinical trials evaluated the effect of dapsone gel, 7.5% based on sex and baseline acne lesion count. Read More

View Article

Download full-text PDF

Source
November 2018
12 Reads